Summary: Researchers have produced the first direct experimental evidence that the severity of a genetic mutation can change sex-based vulnerability to autism spectrum disorder (ASD). While autism is diagnosed about four times more often in males than females, this new study shows that mild mutations spare female resilience, whereas severe mutations can overwhelm it and produce pronounced ASD-like abnormalities in both sexes.
A collaborative team from KAIST, Yonsei University, and the Institute for Basic Science created the world’s first viable homozygous CHD8-mutant mouse model, targeting CHD8 — a prominent genetic risk factor for autism. By comparing mice with one mutated CHD8 copy (heterozygous) to those with mutations in both copies (homozygous), the researchers mapped how mutation strength shifts sex differences in behavior, brain structure, neural activity, and gene expression.
Key Facts
- The Four-Fold Sex Gap: Autism spectrum disorder is diagnosed roughly four times more often in boys than in girls, suggesting that females possess biological mechanisms that reduce vulnerability.
- CHD8 — a chromatin remodeler: CHD8 helps shape chromatin structure and controls a network of genes central to early brain development, making it a major genetic risk factor for ASD and related neurodevelopmental disorders.
- Overcoming embryonic lethality: Prior attempts to produce mice with mutations in both CHD8 copies resulted in embryonic death. Introducing the mutation into a hybrid genetic background allowed viable homozygous mutants to survive.
- Severity shifts sex differences: Heterozygous CHD8 mutants showed behavioral abnormalities primarily in males, while homozygous mutants displayed pronounced ASD-like traits in both males and females.
- Widespread neural disruption: Severe CHD8 mutation led to enlarged brain volume, reduced cerebral blood flow, altered brain rhythms, impaired synaptic transmission, and broad transcriptomic changes affecting synaptic signaling, RNA splicing, and mitochondrial function.
- Fluid biological protection: The results indicate that female resilience to ASD is not fixed; it degrades progressively as the absolute severity of a genetic disruption increases.
CHD8 mutations have been repeatedly linked to ASD, but most animal models carried only heterozygous mutations and produced relatively mild phenotypes. That limited researchers’ ability to study how stronger mutations affect sex differences and severe forms of the condition. By using a hybrid (C57BL6/J × 129/Sv) genetic background, the team avoided embryonic lethality and produced viable homozygous CHD8-Asn2373LysfsX2 mice for the first time.
On the same hybrid background, the researchers compared heterozygous and homozygous CHD8 mutants across multiple measures: developmental trajectories, brain volume, cerebral blood flow, neuronal firing and rhythms, synaptic transmission, and transcriptomic profiles. The comparison revealed a gene dosage-dependent intensification of ASD phenotypes and a concurrent reduction in typical male–female differences.
Heterozygous CHD8+/N2373K mice exhibited behavioral deficits mainly in males, mirroring the higher male prevalence in human ASD. Homozygous CHD8N2373K/N2373K mice, however, developed stronger ASD-related behaviors in both sexes and showed robust structural and functional brain changes. Transcriptomic analyses implicated pathways linked to synaptic function, RNA processing, and mitochondrial activity, offering molecular routes through which mutation strength modulates vulnerability and sex differences.
Professor Eunee Lee of Yonsei University commented that the findings indicate females possess protective biological mechanisms against CHD8-related dysfunction, but that severe mutations can overwhelm those defenses. Director Eunjoon Kim of the IBS Center for Synaptic Brain Dysfunctions emphasized that demonstrating sex differences vary with mutation strength provides a foundation for more precise, individualized therapeutic strategies that consider both biological sex and mutation severity.
Key Questions Answered
A: Longstanding observations show a roughly 4:1 male-to-female diagnostic ratio in ASD, consistent with the idea that females have innate biological protections. This study clarifies that these protections can buffer against mild genetic disruptions but are vulnerable to severe mutations that fundamentally alter neurodevelopment.
Q: How did researchers produce a model that was previously embryonically lethal?
A: The team introduced the human CHD8-Asn2373LysfsX2 mutation into a hybrid genetic background, creating a genetic context that allowed homozygous mutant mice to survive embryonic development and enabling direct study of severe mutation effects.
Q: Does this mean biological sex is irrelevant when treating severe ASD?
A: No. Biological sex remains important, but its influence depends on mutation strength. The study shows sex differences can diminish as mutation severity increases, underscoring the need for precision approaches that account for both a patient’s sex and the genetic intensity of their condition.
Editorial Notes
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by staff.
About this research
Author: William Suh
Source: Institute for Basic Science
Contact: William Suh – Institute for Basic Science
Image: Credit to Neuroscience News
Original Research: “Homozygous CHD8 mutation intensifies ASD phenotypes and attenuates sex differences” by Jinkyeong Kim et al., published in Molecular Psychiatry. DOI: 10.1038/s41380-026-03646-9. The study is open access.
Abstract (summary)
CHD8 is a chromatin remodeler linked to ASD and other neurodevelopmental disorders, but heterozygous Chd8-mutant mouse lines often show only mild ASD-related traits, leaving the gene’s full impact unclear. Because complete knockout causes embryonic lethality, the researchers generated viable homozygous Chd8-mutant mice carrying the human CHD8-Asn2373LysfsX2 mutation on a hybrid genetic background. Compared with heterozygotes, homozygous mice displayed stronger ASD-related behaviors, increased brain volume, reduced cerebral blood volume/flow, altered brain rhythms and synaptic transmission, and transcriptomic alterations in pathways including synaptic signaling, RNA splicing, and mitochondrial function. Importantly, behavioral deficits that were male-predominant in heterozygotes became more balanced across sexes in homozygotes, indicating that mutation strength and genetic background interact to modulate sexual dimorphism in ASD.